Table of Content

1. Introduction to Controlled Drug Delivery
1.1 Fundamentals & Technology Of Controlled Drug Delivery Systems
1.2 Controlled Drug Delivery Classification: By System, Route & Technology
1.3 Controlled Drug Delivery Mechanism of Action


2. Material Based Approaches for Controlled Drug Delivery
2.1 Polymers
2.2 Chronopharmaceutics
2.3 Nanoparticulate Delivery System


3. Global Controlled Release Drug Delivery Market Trends
3.1 Current Market Scenario
3.2 Future Market Outlook


4. Global Controlled Release Drug Regional Market Trends
4.1 US
4.2 Europe
4.3 Japan
4.4 China
4.5 Canada
4.6 South Korea


5. Global Controlled Release Drugs Clinical Pipeline Overview
5.1 Company
5.2 Country
5.3 Drug Class
5.4 Indication
5.5 Patient Segment
5.6 Phase



6. Controlled Drug Delivery Research & Clinical Trends by Indication
6.1 Diabetes
6.2 Cancer
6.3 Cardiovascular Diseases
6.4 Neurological Disorders
6.5 Infections


7. Global Controlled Release Drugs Clinical Pipeline By Company, Indication & Phase
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-II/III
7.7 Phase-III
7.8 Preregistration
7.9 Registered


8. Marketed Controlled Release Drugs Clinical Insight


9. Controlled Release Drugs for Alzheimer’s Disease - Pricing, Patent & Dosage Insight
9.1 Namzaric (Extended-Release)
9.2 Namenda XR (Extended-Release)
9.3 Razadyne ER (Extended-Release)


10. Controlled Release Drugs for Parkinson’s Disease - Pricing, Patent & Dosage Insight
10.1 Gocovri (Extended-Release)
10.2 Osmolex ER (Extended-Release)
10.3 Mirapex ER (Extended-Release)

11. Controlled Release Drugs for Schizophrenia - Pricing, Patent & Dosage Insight
11.1 Perseris (Extended-Release)
11.2 Invega (Extended-Release)
11.3 Invega Sustenna/Invega Trinza/Invega Hafyera (Extended-Release)
11.4 Seroquel XR (Extended-Release)
11.5 Abilify Maintena/ Abilify Asimtufii (Extended-Release)
11.6 Aristada/Aristada Initio (Extended-Release)
11.7 Rykindo (Extended-Release)
11.8 Uzedy (Extended-Release)


12. Controlled Release Drugs for Chronic Pain - Pricing, Patent & Dosage Insight
12.1 Hysingla ER (Extended-Release)
12.2 Nucynta ER (Extended-Release)
12.3 Kadian (Extended-Release)
12.4 Xtampza ER (Extended-Release)
12.5 MS Contin (Extended-Release)
12.6 Embeda (Extended-Release)


13. Controlled Release Drugs for Multiple Sclerosis - Pricing, Patent & Dosage Insight
13.1 Ampyra/Fampyra (Extended-Release)
13.2 Tecfidera (Delayed-Release)
13.3 Rayos (Delayed-Release)
13.4 Vumerity (Delayed-Release)
13.5 Bafiertam (Delayed-Release)


14. Controlled Release Drugs for Diabetes Mellitus Type II - Pricing, Patent & Dosage Insight
14.1 Glumetza (Extended-Release)
14.2 Glucotrol XL (Extended-Release)
14.3 Glucophage XR (Extended-Release)
14.4 Bydureon (Extended-Release)
14.5 Trijardy XR (Extended-Release)


15. Controlled Release Drugs for Hypertension & Angina Pectoris - Pricing, Patent & Dosage Insight
15.1 Procardia XL (Extended-Release)
15.2 Toprol XL (Extended-Release)
15.3 Adalat CC (Extended-Release)
15.4 Verelan PM (Extended-Release)
15.5 Cardizem LA (Extended-Release)


16. Controlled Release Drugs for Post-Operative Pain - Pricing, Patent & Dosage Insight
16.1 Zynrelef (Extended-Release)
16.2 Posimir (Sustained - Release)


17. Controlled Release Drugs for HIV - Pricing, Patent & Dosage Insight
17.1 Apretude extended-release
17.2 Cabenuva extended-release
17.3 Rukobia (Extended-Release)


18. Controlled Release Drugs for Attention Deficit Hyperactivity Disorder - Pricing, Patent & Dosage Insight
18.1 Qelbree (extended-release)
18.2 Jornay PM (Extended-Release)
18.3 Cotempla XR-ODT (Extended-Release)
18.4 Adzenys ER (Extended-Release)


19. Controlled Release Drugs for Inflammatory & Autoimmune Diseases - Pricing, Patent & Dosage Insight
19.1 Rinvoq (Extended-Release)
19.2 Ortikos (Extended-Release)
19.3 Xeljanz XR (Extended-Release)



20. Controlled Release Drugs for Bacterial Infections - Pricing, Patent & Dosage Insight
20.1 Aemcolo (Delayed-Release)
20.2 Talicia (Delayed-Release)

21. Controlled Release Drugs for Opioid Use Disorder - Pricing, Patent & Dosage Insight
21.1 Sublocade (Sustained-Release)
21.2 Brixadi (Extended-Release)

22. Controlled Release Drugs for Preventing Organ Transplant Rejection - Pricing, Patent & Dosage Insight
22.1 Astagraf XL (Extended-Release)
22.2 Envarsus XR (Extended-Release)

23. Global Controlled Drug Delivery Market Dynamics
23.1 Market Drivers
23.2 Market Restraints

24. Competitive Landscape
24.1 AbbVie
24.2 Antlia Bioscience
24.3 Arbor Pharmaceuticals (Azurity Pharmaceuticals)
24.4 AstraZeneca
24.5 Bausch Health Companies
24.6 Biodexa Pharmaceuticals
24.7 Camurus
24.8 DURECT Corporation
24.9 Emplicure
24.10 Endo International
24.11 HLK Pharmacin
24.12 Jemincare
24.13 Johnson & Johnson
24.14 Luye Pharma Group
24.15 Lyndra
24.16 Mallinckrodt plc
24.17 MedinCell S.A.
24.18 Merck
24.19 Otsuka Pharmaceutical
24.20 Pacira BioSciences
24.21 Pfizer
24.22 Purdue Pharma
24.23 Roche
24.24 Sanofi
24.25 Serina Therapeutics
24.26 Sun Pharmaceutical Industries
24.27 Supernus Pharmaceuticals
24.28 Takeda
24.29 Tris Pharma
24.30 ViiV Healthcare



List of Tables

Table 1-1: Major Differences between Conventional & Novel Drug Delivery Systems
Table 1-2: Comparison of Sustained Drug Release & Controlled Drug Release
Table 4-1: US FDA – Some Recently Approved Controlled Release Drugs